Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-01
2008-01-01
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S483000
Reexamination Certificate
active
11256572
ABSTRACT:
Disclosed herein are compounds of Formula (I), (II), and (III)pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.
REFERENCES:
patent: 1792355 (1931-02-01), Boeniger
patent: 3148192 (1964-09-01), Velluz
patent: 3150151 (1964-09-01), Urbschaft et al.
patent: 3208991 (1965-09-01), Blout et al.
patent: 3718678 (1973-02-01), Farrand et al.
patent: 3754857 (1973-08-01), McKay
patent: 3966900 (1976-06-01), Hennart et al.
patent: 4322533 (1982-03-01), Lesher et al.
patent: 4451398 (1984-05-01), Patsch et al.
patent: 4720304 (1988-01-01), Ruff et al.
patent: 5001229 (1991-03-01), Franke et al.
patent: 5051417 (1991-09-01), Nadler et al.
patent: 5155015 (1992-10-01), Jimbo
patent: 5164404 (1992-11-01), Dahl et al.
patent: 5298658 (1994-03-01), Fabricius
patent: 5482546 (1996-01-01), Eida
patent: 5766581 (1998-06-01), Bartley et al.
patent: 6075044 (2000-06-01), Wang et al.
patent: 6448238 (2002-09-01), Shoichet et al.
patent: 6552008 (2003-04-01), Duffy et al.
patent: 6642265 (2003-11-01), Leungo et al.
patent: 6649631 (2003-11-01), Orme et al.
patent: 6670387 (2003-12-01), Luengo et al.
patent: 6720345 (2004-04-01), Luengo et al.
patent: 6875786 (2005-04-01), Duffy et al.
patent: 6964701 (2005-11-01), Foster et al.
patent: 6964977 (2005-11-01), Harris et al.
patent: 7026334 (2006-04-01), Takemoto et al.
patent: 7071217 (2006-07-01), Dickerson et al.
patent: 7105529 (2006-09-01), Davis et al.
patent: 7129253 (2006-10-01), Glennon et al.
patent: 7135550 (2006-11-01), Come
patent: 7160870 (2007-01-01), Duffy et al.
patent: 2003/0229453 (2003-12-01), Antonysamy et al.
patent: 2004/0019190 (2004-01-01), Erickson-Miller et al.
patent: 2004/0024040 (2004-02-01), Green et al.
patent: 2004/0053299 (2004-03-01), Delorme et al.
patent: 2004/0058990 (2004-03-01), Duffy et al.
patent: 2004/0082626 (2004-04-01), Takemoto et al.
patent: 2004/0220146 (2004-11-01), Freeman et al.
patent: 2004/0253178 (2004-12-01), Atwell et al.
patent: 2005/0049267 (2005-03-01), Suto et al.
patent: 2005/0153977 (2005-07-01), Sugasawa et al.
patent: 2005/0234020 (2005-10-01), Heerding
patent: 2006/0069140 (2006-03-01), Miyaji et al.
patent: 2006/0084682 (2006-04-01), Heerding et al.
patent: 2006/0094694 (2006-05-01), Owada et al.
patent: 2006/0116417 (2006-06-01), Chen et al.
patent: 2006/0178518 (2006-08-01), Moore
patent: 2007/0105824 (2007-05-01), Erickson-Miller et al.
patent: 653800 (1965-03-01), None
patent: 193633 (1907-02-01), None
patent: 450819 (1927-10-01), None
patent: 4335623 (1995-04-01), None
patent: 0141067 (1984-08-01), None
patent: 0335237 (1989-03-01), None
patent: 1080864 (1967-08-01), None
patent: 2 168 347 (1986-06-01), None
patent: 2-287457 (1990-11-01), None
patent: 2000-206645 (2000-07-01), None
patent: 2001-152055 (2001-05-01), None
patent: 2002-020641 (2002-01-01), None
patent: 2002-129072 (2002-05-01), None
patent: 2002-129073 (2002-05-01), None
patent: 2003-128946 (2003-05-01), None
patent: 2003-313450 (2003-11-01), None
patent: 2003-335972 (2003-11-01), None
patent: 2004-143118 (2004-05-01), None
patent: WO 01/21180 (2001-03-01), None
patent: WO 01/89457 (2001-11-01), None
patent: WO 03/037905 (2003-05-01), None
patent: WO 03/082265 (2003-09-01), None
patent: WO 03/103686 (2003-12-01), None
patent: WO 2005/097119 (2005-10-01), None
patent: WO 2005/107466 (2005-11-01), None
patent: WO 2005/118551 (2005-12-01), None
patent: WO 2006/004545 (2006-01-01), None
patent: WO 2006/052936 (2006-05-01), None
patent: WO 2006/076442 (2006-07-01), None
patent: PCT/US2007/00654 (2007-01-01), None
patent: WO 2007/062078 (2007-05-01), None
Bains et al. “Silicon chemistry as a novel source of chemical diversity in drug design.”Current Opinion in Drug Discovery and Development; 6(4):526-543 (2003).
Bartley et al. “Identification and Cloning of a Megakaryocyte Growth and Development Factor That Is a Ligand for the Cytokine Receptor Mpl.”Cell; 77:1117-11124 (1994).
Basser et al. “Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer.”Blood; 89(9):3118-3128 (1997).
Cwirla et al. “Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine”.Science; 276:1696-1699 (1997).
Database Beilstein. Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP-002364395. Database accession No. BRN: 1499659; BRN: 1554046; BRN: 1554047.
Database Beilstein. Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP-002364396. Database accession No. BRN: 1513709.
Database Caplus Chemical Abstracts Service, Columbus, Ohio, US; XP-002364397 retrieved from STN accession No. 1978: 443178 Database accession No. 89: 43178.
de Sauvage et al. “Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand”.Nature; 369:533-538 (1994).
Fanucchi et al. “Effects of Polyethylene Glycol-Conjugated Recombinant Human Megakaryocyte Growth and Development Factor on Platelet Counts After Chemotherapy for Lung Cancer.”New England J. Med.; 336(6):404-409 (1997).
Kuter, David J. “Thrombopoietin: Biology and Clinical Applications.”The Oncologist; 1:98-106 (1996).
Kuter et al. “The purification of megapoietin: A physiological regulator of Megakaryocyte growth and platelet production.”Proc. Natl. Acad. Sci.; 91:11104-11108 (1994).
Lamb et al. “STAT protein complexes activated by interferon-γ and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties.”Nucleic Acids Research; 23(16): 3283-3289 (1995).
Lok et al. “Cloning and expression of murine Thrombopoietin cDNA and stimulation of platelet production in vivo.”Nature; 369: 565-568 (1994).
Metcalf, Donald. “Thrombopoietin—at last.”Nature; 369:519-520 (1994).
Seidel et al. “Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity.”Proc. Nat. Acad. Sci. USA; 92: 3041-3045 (1995).
Tacke et al. “Sila-substitution—a useful strategy for drug design?”New Series; 10(4):191-197 (1986).
Vigon et al. “Molecular cloning and characterization ofMPL, the human homolog of the v-mploncogene: Identfication of a member of the hematopoietic growth factor receptor superfamily.”Natl. Acad. Sci. USA; 89:5640-5644 (1992).
Wendling et al. “c-MPL ligand as a humoral regulator of megakaryocytopoiesis.”Nature; 369:571-574 (1994).
Wendling et al. “Mpl ligand or Thrombopoietin: Biological activities.”Biotherapy; 10:269-77 (1998).
Abdel-Latif et al., “Reaction of Diazocompounds and Hydrazines on Indolin-2-one Derivatives”,Indian J. Chem., 1985, 24B(7), 775-777.
Abdel-Rahman et al., “Synthesis of some 1,2,4-Triazino [4,3-a] indole derivatives”,J. Indian Chem. Soc., 1991, 68(11), 621-624.
Abdel-Rahman et al., “Synthesis of Some New 2,3/2,4-Disubstituted-1,2,4-Trianzino [5,6-b] Indoles”,Asian J. Chem., 1992, 4(2), 364-371.
Alam et al., “Analytical studies of biologically active compounds-I: Quantitative Determination of Metabolies of 3-Substituted Isatin Derivatives by TLC”,Proc. Pakistan Acad. Sci., 1992, 29(2), 113-120.
Alam et al., “Biopharmaceutical Studies of 3-Substituted Isatin Derivatives”,Indian J. Exp. Biol., 1990, 28(10), 940-942.
Alam et al., “Electronic Spectra of Isatin Derivatives”,Proc. Pakistan Acad. Sci., 1987, 24(4), 337-348.
Ali, et al., “Analytical Studies on Biologically Active Compounds. Part II. Separation and Quantitation of Mixtures of Isatin Derivatives for Application to Metabolis
Chen Jyun-Hung
Dalgard Jackline E.
Kallel E. Adam
Lau Thomas
McNeill Matthew H.
Anderson Rebecca
Knobbe Martens Olson & Bear LLP
Ligand Pharmaceuticals Inc.
Nolan Jason M
LandOfFree
Thrombopoietin activity modulating compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thrombopoietin activity modulating compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombopoietin activity modulating compounds and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3906184